Tuesday , October 24 2017
Home / Health / Novartis says Votubia receives EU approval for new indication

Novartis says Votubia receives EU approval for new indication


ZURICH (Reuters) – Novartis has broadened the indications for its Votubia drug, the corporate stated on Tuesday, when the European Union authorised its use to deal with refractory partial-onset seizures in sufferers with tuberous sclerosis complicated.

Votubia is the primary adjunctive remedy authorised within the EU particularly for partial-onset seizures in youngsters and adults with tuberous sclerosis complicated, the Basel-based prescription drugs firm stated in a press release.

The choice marks the third TSC-related indication for Votubia within the EU, the place it’s also permitted to deal with subependymal big cell astrocytoma and renal angiomyolipomas.

Tuberous sclerosis complicated is a uncommon genetic dysfunction affecting as much as a million individuals worldwide. Approximately 85 % of people with TSC are affected by epilepsy, and uncontrolled seizures related to TSC could be debilitating for sufferers.

(Reporting by John Revill)


Source link

Check Also

What do you need to know about a polypectomy?

We look the polypectomy process, together with the varied surgical choices, surgical dangers and restoration …

Leave a Reply

Your email address will not be published. Required fields are marked *

*